Since a peak in 1991, cancer mortality rates have declined by as much as 27% around the world. These gains in cancer survival are largely attributed to new and innovative therapies. According to the CDC, for patients with childhood leukemia, prostate, and breast cancers, five-year survival has increased steadily in most developed countries, with some countries reporting five-year survival rates of more than 85%.
New treatments continue to alter the course of previously fatal diseases and there are now more promising cancer medicines in the pipeline than at any time in history. Personalized medicines such as immunotherapy are transforming cancer care in ways never before seen, using patients’ immune systems to fight or eliminate cancers.
To learn more check out our International Cost in Context information.
Giovanni Caforio M D
Dr. Caforio, M.D. serves as Chairman of Bristol Myers Squibb’s Board of Directors. Dr. Caforio has been BMS’ Chief Executive Officer since May 2015. He was our Chief Executive Officer Designate from January to May 2015, our Chief Operating Officer from June 2014 to May 2015, and he served as Executive Vice President and Chief Commercial Officer from November 2013 to June 2014. From October 2011 to November 2013, he served as President, U.S. He held the position of Senior Vice President, Global Commercialization and Immunology from May 2010 to October 2011. Prior to that, he served as Senior Vice President, Oncology, U.S. and Global Commercialization from March 2009 to May 2010. From January 2007 to March 2009 he served as Senior Vice President, U.S. Oncology and from May 2004 to January 2007, he served as Senior Vice President, European Marketing and Brand Commercialization. Dr. Caforio is a member of the Board of Trustees of Hun School of Princeton and a member of the Business Roundtable, CEO Roundtable on Cancer and serves as Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) and The Prium.
Giovanni Caforio M D
Bayh-Dole: The fuel for America’s innovation engine
ICYMI: Biopharmaceutical companies in America hit new investment milestone
New study: HPV vaccination helps prevent cervical cancer deaths
Staffing up: Building the future biopharma workforce to keep America in the lead
New report explores setbacks that bring future cancer success stories
Research and Development
PhRMA Member Company
Cancer
New Era of Medicine
New report explores setbacks that bring future cancer success stories
New report explores setbacks that bring future cancer success stories